Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Current Opinion in Oncology|May 21, 2014
Poly(ADP-ribose) polymerase inhibitors in Ewing sarcomaBritta Vormoor, Nicola J Curtin
Oncotarget|January 27, 2018
Sensitizing Ewing sarcoma to chemo- and radiotherapy by inhibition of the DNA-repair enzymes DNA protein kinase (DNA-PK) and poly-ADP-ribose polymerase (PARP) 1/2Britta Vormoor, Yvonne T Schlosser, Helen Blair, et al.
BMJ Open|March 5, 2022
Selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult acute lymphoblastic leukaemia (SeluDex): study protocol for an international, parallel-group, dose-finding with expansion phase I/II trialTobias Menne, Daniel Slade, Joshua Savage, et al.
Plos One|January 11, 2014
Development of a preclinical orthotopic xenograft model of ewing sarcoma and other human malignant bone disease using advanced in vivo imagingBritta Vormoor, Henrike K Knizia, Michael A Batey, et al.
European Journal of Cancer (Oxford, England : 1990)|February 5, 2022
Targeted inhibitors and antibody immunotherapies: Novel therapies for paediatric leukaemia and lymphomaErica Brivio, André Baruchel, Auke Beishuizen, et al.
Leukemia|October 31, 2022
Outcome of chimeric antigen receptor T-cell therapy following treatment with inotuzumab ozogamicin in children with relapsed or refractory acute lymphoblastic leukemiaValeria Ceolin, Erica Brivio, Harm van Tinteren, et al.
Leukemia|April 26, 2022
CD19 CAR T-cells for pediatric relapsed acute lymphoblastic leukemia with active CNS involvement: a retrospective international studyElad Jacoby, Sara Ghorashian, Britta Vormoor, et al.
Leukemia|May 19, 2021
MAPK-ERK is a central pathway in T-cell acute lymphoblastic leukemia that drives steroid resistanceJordy C G van der Zwet, Jessica G C A M Buijs-Gladdines, Valentina Cordo', et al.
Blood Advances|February 8, 2022
Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemiaLinde Dekker, Friso G Calkoen, Yilin Jiang, et al.
Leukemia|April 26, 2022
Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trialEdoardo Pennesi, Naomi Michels, Erica Brivio, et al.
Pageof 1